Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Patients by Transient Addition of BRAF and MEK Inhibitors Followed by Pembrolizumab: A Pivotal Open Label, Single-site Study

NCT05304546 is registered in ClinicalTrials.gov with Dr. Ronnie Shapira as lead sponsor.

NCT NCT05304546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Patients by Transient Addition of BRAF and MEK Inhibitors Followed by Pembrolizumab: A Pivotal Open Label, Single-site Study
Lead sponsor
Dr. Ronnie Shapira
Phase
Phase 2
Overall status
Completed
Start date
September 5, 2023
Completion date
July 17, 2025
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e, immunotherapy, malignant melanoma, malignant melanoma stage iv, metastatic melanoma